Spin fails to spark for Genesis after $9.6 million loss

Genesis posted a $9.6 million loss, in line with its 2000 float forecast of $9.1 million. It presented a "bright side" by emphasising it had $47.9 million in cash, down from $61 million a year ago.

"All that demonstrates is that they've burned another $13 million of cash without generating any additional revenue," one analyst commented. Revenue fell $8.7 million to $20 million.

CEO Jim Watson said the company had reached agreement with the US Food and Drug Administration on the next phase of trials of its PVAC psoriasis vaccine.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

CVT - Comvita Limited director nominations
September 4th Morning Report
BRW - Revised offer from Floorscape Limited for 100% of Bremworth
WIN - Winton Appoints Michael Stiassny as Independent Chair
WCO - Offer of new shares to selected investors
GNE - Genesis secures additional gas to strengthen fuel portfolio
FSF - Fonterra provides update on forecast FY26 earnings
September 2nd Morning Report
TWL - Amendments to Notice of Annual Shareholders' Meeting
Devon Funds Morning Note - 01 September 2026